Trials / Completed
CompletedNCT02616822
Effects of Trans-Resveratrol in Endothelial Function in Hypertensive Patients
Acute Effects Of Trans-Resveratrol in Endothelial Function in Treated Hypertensive Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Hospital Universitario Pedro Ernesto · Academic / Other
- Sex
- All
- Age
- 45 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Arterial Hypertension (HBP) has a high prevalence and low rates of control, is considered a major modifiable risk factors and one of the most important public health problems. Mortality from cardiovascular disease increases progressively with increasing blood pressure (BP) in a linear, continuous and independent. The pathophysiological mechanisms involved in the pathogenesis of hypertension exhibit metabolic abnormalities, which are related to endothelial dysfunction. Resveratrol, a polyphenol stilbene derived from various species of plants, but in our food, mainly present in red wine and grapes, has shown protective effects in cardiovascular diseases, such as preventing the damage caused by oxidative stress, decreased plasma lipids with inhibiting the formation of atherosclerotic plaque; protective effect of vascular endothelium, with increased release of nitric oxide and decreased production of free radicals in animal models, but human studies are limited and insufficient to clarify the possible effects of trans-resveratrol (biologically active form) on endothelial function, blood pressure and central aortic pressure in treated hypertensive individuals.The aim of this study is to evaluate the acute effects of trans-resveratrol supplementation on endothelial function in treated hypertensive patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Trans-resveratrol | Used for trans-resveratrol substance 300 mg single dose |
| OTHER | Placebo | Used for placebo substance single dose |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2015-11-30
- Last updated
- 2015-11-30
Source: ClinicalTrials.gov record NCT02616822. Inclusion in this directory is not an endorsement.